Factors influencing false-positive results of rifampicin resistance detected by Xpert MTB/RIF: A retrospective study in Zhejiang, China

被引:0
|
作者
Wu, Guihua [1 ]
Wang, Jing [1 ]
Xu, Xiaoqun [1 ]
Wei, Hui [1 ]
Cai, Long [1 ]
Liu, Libin [1 ]
机构
[1] Hangzhou Red Cross Hosp, Ctr Lab Med, Hangzhou, Zhejiang, Peoples R China
关键词
Rifampicin resistance; Probe mutation; Probe delay; Influencing factors; MYCOBACTERIUM-TUBERCULOSIS; MUTATION; ASSAY;
D O I
10.1016/j.heliyon.2024.e31680
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objective: This study aimed to explore the factors influencing false-positive results for rifampicin resistance (RIF-R) detected using Xpert MTB/RIF (Xpert). Methods: This retrospective analysis included the clinical data of patients from September 2019 to February 2023. The chi-square and rank sum tests were used to compare differences in patient characteristics between the true-positive and false-positive groups. Logistic regression was used to analyze the factors influencing false positives in the detection of RIF-R by Xpert. Results: A total of 384 patients were included. Logistic regression analysis revealed that, with mutation of probe E as the reference, mutations on probe A or C (OR = 72.68, P < 0.001), probe D (OR = 6.44, P < 0.001), and multiple probes (OR = 5.94, P = 0.002) were associated with false-positive results in Xpert detection of RIF-R. Taking probe delay Delta Ct <4 as the reference, Delta Ct (4-5.9) (OR = 13.54, P < 0.001), Delta Ct (6-7.9) (OR = 48.08, P < 0.001) probe delays were associated with false positives in Xpert detection of RIF-R. When very low quantification is accompanied by a probe delay, the probability of false-positive RIF-R detection can reach 80 %. Conclusions: Clinicians should consider factors such as probe mutation type, probe delay, and very low quantification accompanied by probe delay when interpreting Xpert results, which can reduce the misdiagnosis of tuberculosis drug resistance.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Detection of Rifampicin Resistance among Patients with Tuberculosis using GeneXpert MTB/RIF Assay: A Retrospective Study
    Durairaj, Gayathridevi
    Rathinam, Sridhar
    Vishwanathan, Vinodkumar
    Satagopan, Kumar
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2020, 14 (09)
  • [42] Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study
    Soeroto, Arto Yuwono
    Lestari, Bony Wiem
    Santoso, Prayudi
    Chaidir, Lidya
    Andriyoko, Basti
    Alisjahbana, Bachti
    van Crevel, Reinout
    Hill, Philip C.
    PLOS ONE, 2019, 14 (02):
  • [43] Dependence of Xpert MTB/RIF Accuracy for Detecting Rifampin Resistance in Bronchoalveolar Lavage Fluid on Bacterial Load: A Retrospective Study in Beijing, China
    Qin, Lin
    Huo, Fengmin
    Ren, Weicong
    Shang, Yuanyuan
    Yao, Cong
    Zhang, Xuxia
    Liu, Rongmei
    Ma, Liping
    Gao, Mengqiu
    Pang, Yu
    INFECTION AND DRUG RESISTANCE, 2021, 14 : 2429 - 2435
  • [44] Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert® MTB/RIF in Kampala, Uganda: a retrospective study
    Mboowa, Gerald
    Namaganda, Carolyn
    Ssengooba, Willy
    BMC INFECTIOUS DISEASES, 2014, 14
  • [45] Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert®MTB/RIF in Kampala, Uganda: a retrospective study
    Gerald Mboowa
    Carolyn Namaganda
    Willy Ssengooba
    BMC Infectious Diseases, 14
  • [46] Frequency of MTB and rifampicin resistance MTB using Xpert-MTB/RIF assay among adult presumptive tuberculosis patients in Tigray, Northern Ethiopia: A cross sectional study
    Wasihun, Araya Gebreyesus
    Dejene, Tsehaye Asmelash
    Hailu, Genet Gebrehiwet
    PLOS ONE, 2020, 15 (11):
  • [47] Does Xpert® MTB/RIF assay give rifampicin resistance results without identified mutation? Review of cases from Addis Ababa, Ethiopia
    Alemu, Ayinalem
    Tadesse, Mengistu
    Seid, Getachew
    Mollalign, Helina
    Eshetu, Kirubel
    Sinshaw, Waganeh
    Abebaw, Yeshiwork
    Amare, Misikir
    Dagne, Biniyam
    Diriba, Getu
    Yenew, Bazezew
    Getu, Melak
    Zerihun, Betselot
    BMC INFECTIOUS DISEASES, 2020, 20 (01)
  • [48] Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert MTB/RIF in Khyber Pakhtunkhwa, Pakistan: a retrospective study
    Irfan Ullah
    Aamer Ali Shah
    Anila Basit
    Mazhar Ali
    Afsar khan
    Ubaid Ullah
    Muhammad Ihtesham
    Sumaira Mehreen
    Anita Mughal
    Arshad Javaid
    BMC Infectious Diseases, 16
  • [49] Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert MTB/RIF in Khyber Pakhtunkhwa, Pakistan: a retrospective study
    Ullah, Irfan
    Shah, Aamer Ali
    Basit, Anila
    Ali, Mazhar
    Khan, Afsar
    Ullah, Ubaid
    Ihtesham, Muhammad
    Mehreen, Sumaira
    Mughal, Anita
    Javaid, Arshad
    BMC INFECTIOUS DISEASES, 2016, 16
  • [50] Screening for HIV-Associated Tuberculosis and Rifampicin Resistance before Antiretroviral Therapy Using the Xpert MTB/RIF Assay: A Prospective Study
    Lawn, Stephen D.
    Brooks, Sophie V.
    Kranzer, Katharina
    Nicol, Mark P.
    Whitelaw, Andrew
    Vogt, Monica
    Bekker, Linda-Gail
    Wood, Robin
    PLOS MEDICINE, 2011, 8 (07)